NDSN Stock Analysis: Nordson | NASDAQ
Specialty Industrial Machinery | NASDAQ, USA | Market Cap: 18.332m USD | 12M Return: 41.2% | US6556631025 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 112M
EPS Trend: 95.3%
Qual. Beats: 1
Rev. Trend: 94.2%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nordson Corporation (NDSN) is a U.S.-based industrial machinery company that engineers, manufactures, and markets precision dispensing, coating, and fluid control systems for a diverse range of industries. The company operates through three segments: Industrial Precision Solutions, Medical and Fluid Solutions, and Advanced Technology Solutions, serving end markets that include packaging, consumer nonwovens, medical devices, electronics, and semiconductors. Its product portfolio spans adhesive dispensing systems, fluid components such as nozzles and pumps, medical tubing and interventional delivery components, and automated testing equipment like bond testers and x-ray inspection systems.
Founded in 1909 and headquartered in Westlake, Ohio, Nordson has been publicly traded since 1990 and is classified within the Industrials sector under Industrial Machinery & Supplies. The company reaches customers through a multi-channel sales approach combining a direct sales force, distributors, and sales representatives. Its diversified business model-spanning industrial production, medical, and advanced technology applications-provides exposure to several distinct demand drivers and helps reduce reliance on any single end market.
- Semiconductor inspection demand drives Advanced Technology Solutions segment growth
- Nonwovens and hygiene product demand supports Industrial Precision Solutions revenue
- Medical device segment margins expand on interventional solutions growth
| Net Income: 555.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 3.21 > 1.0 |
| NWC/Revenue: 20.12% < 20% (prev 19.53%; Δ 0.59% < -1%) |
| CFO/TA 0.13 > 3% & CFO 777.9m > Net Income 555.2m |
| Net Debt (1.79b) to EBITDA (947.4m): 1.89 < 3 |
| Current Ratio: 1.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.0m) vs 12m ago -1.77% < -2% |
| Gross Margin: 55.29% > 18% (prev 54.56%; Δ 0.73% > 0.5%) |
| Asset Turnover: 49.84% > 50% (prev 46.33%; Δ 3.51% > 0%) |
| Interest Coverage Ratio: 6.98 > 6 (EBIT TTM 799.9m / Interest Expense TTM 114.5m) |
| A: 0.10 (Total Current Assets 1.33b - Total Current Liabilities 728.5m) / Total Assets 5.95b |
| B: 0.82 (Retained Earnings 4.87b / Total Assets 5.95b) |
| C: 0.13 (EBIT TTM 799.9m / Avg Total Assets 5.98b) |
| D: 1.22 (Book Value of Equity 3.27b / Total Liabilities 2.68b) |
| Altman-Z'' = 5.51 = AAA |
| DSRI: 1.03 (Receivables 648.8m/589.0m, Revenue 2.98b/2.78b) |
| GMI: 0.99 (GM 54.56% / 55.29%) |
| AQI: 1.00 (AQ_t 0.68 / AQ_t-1 0.68) |
| SGI: 1.07 (Revenue 2.98b / 2.78b) |
| TATA: -0.04 (NI 555.2m - CFO 777.9m) / TA 5.95b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of October 09, 2026, the stock is trading at USD 326.87 with a total of 390,545 shares traded. Over the past week, the price has changed by -0.65%, over one month by +3.49%, over three months by +15.49% and over the past year by +41.23%.
Current recommended Stop Loss: 319.20 (which is 2.3% or 1.2 ATR below the current price).
Nordson has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy NDSN.
- StrongBuy: 4
- Buy: 0
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 349.7 | 7% |
P/E Trailing = 33.2343
P/E Forward = 24.7525
P/S = 6.1502
P/B = 5.4765
P/EG = 1.8315
Revenue TTM = 2.98b USD
EBIT TTM = 799.9m USD
EBITDA TTM = 947.4m USD
Long Term Debt = 1.53b USD (from longTermDebt, last quarter)
Short Term Debt = 227.1m USD (from shortTermDebt, last quarter)
Debt = 1.90b USD (from shortLongTermDebtTotal, last quarter) + Leases 87.2m
Net Debt = 1.79b USD (calculated: Debt 1.90b - CCE 113.4m)
Enterprise Value = 20.1b USD (18.3b + Debt 1.90b - CCE 113.4m)
Interest Coverage Ratio = 6.98 (Ebit TTM 799.9m / Interest Expense TTM 114.5m)
EV/FCF = 27.62x (Enterprise Value 20.1b / FCF TTM 728.5m)
FCF Yield = 3.62% (FCF TTM 728.5m / Enterprise Value 20.1b)
FCF Margin = 24.45% (FCF TTM 728.5m / Revenue TTM 2.98b)
Net Margin = 18.63% (Net Income TTM 555.2m / Revenue TTM 2.98b)
Gross Margin = 55.29% ((Revenue TTM 2.98b - Cost of Revenue TTM 1.33b) / Revenue TTM)
Gross Margin QoQ = 55.49% (prev 54.54%)
Tobins Q-Ratio = 3.38 (Enterprise Value 20.1b / Total Assets 5.95b)
Interest Expense / Debt = 6.02% (Interest Expense 114.5m / Debt 1.90b)
Taxrate = 17.69% (119.3m / 674.5m)
NOPAT = 658.4m (EBIT 799.9m * (1 - 17.69%))
Current Ratio = 1.82 (Total Current Assets 1.33b / Total Current Liabilities 728.5m)
Debt / Equity = 0.58 (Debt 1.90b / totalStockholderEquity, last quarter 3.27b)
Debt / EBITDA = 1.89 (Net Debt 1.79b / EBITDA 947.4m)
Debt / FCF = 2.45 (Net Debt 1.79b / FCF TTM 728.5m)
Total Stockholder Equity = 3.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.29% (Net Income 555.2m / Total Assets 5.95b)
RoE = 17.59% (Net Income TTM 555.2m / Total Stockholder Equity 3.16b)
RoCE = 17.07% (EBIT 799.9m / Capital Employed (Equity 3.16b + L.T.Debt 1.53b))
RoIC = 12.35% (NOPAT 658.4m / Invested Capital 5.33b)
WACC = 9.22% (E(18.3b)/V(20.2b) * Re(9.66%) + D(1.90b)/V(20.2b) * Rd(6.02%) * (1-Tc(0.18)))
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.61 | Cagr: -1.28%
[DCF] Terminal Value 75.21% ; FCFF base≈654.3m ; Y1≈750.0m ; Y5≈1.10b
[DCF] Fair Price = 226.5 (EV 14.4b - Net Debt 1.79b = Equity 12.6b / Shares 55.7m; r=9.22% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.32 | EPS CAGR: 8.06% | SUE: 2.51 | # QB: 1
Revenue Correlation: 94.24 | Revenue CAGR: 4.34% | SUE: 2.71 | # QB: 1
EPS current Quarter (2027-01-31): EPS=2.60 | Chg30d=+2.09% | Revisions=+40% | Analysts=3
EPS current Year (2026-10-31): EPS=11.95 | Chg30d=+3.08% | Revisions=+70% | GrowthEPS=+16.7% | GrowthRev=+9.5%
EPS next Year (2027-10-31): EPS=12.98 | Chg30d=+3.43% | Revisions=+70% | GrowthEPS=+8.7% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: +84% (up=16, down=0)